You have been consistent. You have followed your healthcare provider’s guidance on diet, exercise, and medication. And for a while, the results showed on the scale. Then it stopped. If your weight has plateaued on Wegovy 2.4mg, you are not alone — and importantly, a new option is arriving in Singapore.
Wegovy 7.2mg, a higher-dose formulation of semaglutide, has completed its clinical trial programme and demonstrated meaningful additional weight loss for patients who had reached a plateau on the standard 2.4mg maintenance dose. NuLifeCare is among the select clinics in Singapore preparing to offer this new dosage under the Health Sciences Authority (HSA) Named Patient Programme.
Why Does Weight Loss Plateau on Wegovy 2.4mg?
Weight loss plateaus are a well-documented phenomenon in obesity medicine. The body has powerful homeostatic mechanisms that resist weight loss. As you lose weight, your resting metabolic rate decreases, hunger hormones like ghrelin increase, and your body becomes more efficient at storing energy. This is not a personal failure — it is biology.
For many patients on semaglutide 2.4mg, initial weight loss of 10-15% of body weight is common in the first year. However, studies show that weight loss typically reaches a plateau around week 60-68 of treatment. At this point, the 2.4mg dose has achieved what it can for your physiology, and further progress requires a different approach.
What Is Wegovy 7.2mg?
Wegovy 7.2mg is a higher-dose formulation of semaglutide, the same active ingredient found in Wegovy 2.4mg. It belongs to the GLP-1 receptor agonist class of medications, which work by mimicking the glucagon-like peptide-1 hormone that regulates appetite, slows gastric emptying, and signals satiety to the brain.
The 7.2mg dose delivers three times the amount of semaglutide compared to the standard 2.4mg maintenance dose. It is administered as a once-weekly subcutaneous injection, just like the lower-dose formulations patients are already familiar with. The higher dose is intended for patients whose weight loss has stalled on 2.4mg and who may benefit from additional pharmacological support to continue their weight management journey.
The Step Up Trial: Key Findings
The STEP UP trial, conducted between 1 January 2023 and 26 November 2024, was a randomised clinical trial that evaluated the efficacy and safety of semaglutide 7.2mg compared to 2.4mg and placebo. The results were significant:
- Up to 20.7% average weight loss for participants who were fully adherent to both the treatment protocol and recommended lifestyle changes
- An additional ~3% weight loss for patients whose weight had reached a plateau under Wegovy 2.4mg, demonstrating that the higher dose can overcome the treatment ceiling observed with the standard maintenance dose
- The safety profile of the 7.2mg dose was consistent with the known GLP-1 receptor agonist class, with gastrointestinal side effects being the most commonly reported
These findings are clinically meaningful. For a patient weighing 100kg, an additional 3% translates to approximately 3kg of further weight loss beyond what 2.4mg achieved — and for fully adherent patients, the total loss of 20.7% represents a transformative 20.7kg reduction from starting weight.
Who Is Wegovy 7.2mg Suitable For?
Wegovy 7.2mg is intended for patients who meet both of the following criteria:
- Currently on Wegovy 2.4mg and tolerating it well — the 7.2mg dose is a step up from 2.4mg, so patients must have demonstrated good tolerance to the lower dose before considering an increase
- Weight loss has plateaued — if you have been on 2.4mg for several months and your weight has remained stable despite adherence to lifestyle modifications, you may be a candidate for dose escalation
It is important to understand that Wegovy 7.2mg is not a first-line treatment. It is a prescription-only medication that must be initiated and supervised by a licensed doctor. At NuLifeCare, our medical team conducts a comprehensive assessment — including medical history review, physical examination, and relevant blood tests — before recommending any weight management treatment.
Important: Weight management outcomes vary between individuals. The trial data reflects average results across a large study population. Your personal results will depend on factors including your starting weight, metabolic health, adherence to treatment, diet, physical activity, and other individual variables.
How NuLifeCare Brings Wegovy 7.2mg to Singapore
Wegovy 7.2mg has not yet received full marketing authorisation from the Health Sciences Authority (HSA) for general sale in Singapore. However, NuLifeCare is among the select clinics in Singapore that will be directly importing Wegovy 7.2mg under the HSA Named Patient Programme.
The Named Patient Programme allows registered medical practitioners to import unregistered therapeutic products for specific patients under their care when there is a genuine clinical need and no suitable registered alternative is available. In the case of patients who have plateaued on Wegovy 2.4mg, the 7.2mg dose represents a clinically appropriate escalation that is not otherwise available in Singapore.
The Import Process: What to Expect
The overall process of importing Wegovy 7.2mg under the Named Patient Programme typically takes up to eight weeks from the point of patient registration. Here is what the timeline involves:
| Stage | Estimated Duration | What Happens |
|---|---|---|
| 1. Doctor Consultation | 1-2 days | Our medical team assesses your suitability. If clinically appropriate, you are registered for the programme. |
| 2. HSA Application | 2-4 weeks | NuLifeCare submits the Named Patient application to HSA on your behalf. |
| 3. Product Shipment | 2-3 weeks | Once HSA approval is obtained, the medication is shipped from the manufacturer to Singapore. |
| 4. Delivery to Clinic | 3-5 days | The product arrives at NuLifeCare. You are contacted to schedule your appointment. |
Throughout this period, you continue with your current treatment plan under your doctor’s supervision. No gap in care is required while awaiting the 7.2mg formulation.
Frequently Asked Questions
Q: Is Wegovy 7.2mg safe?
The STEP UP trial found the safety profile of semaglutide 7.2mg to be consistent with the known GLP-1 receptor agonist class. The most common side effects were gastrointestinal in nature (nausea, diarrhoea, constipation). As with any prescription medication, our doctor will discuss potential risks and side effects during your consultation.
Q: Can I switch directly from 2.4mg to 7.2mg?
Dose escalation protocols will be determined by your doctor based on your individual medical history and treatment response. A direct switch may not be appropriate for all patients.
Q: How much does Wegovy 7.2mg cost?
Costs are discussed during the consultation as they depend on the Named Patient Programme arrangement and individual treatment plan. Please contact the clinic for details.
Q: Do I need to be an existing NuLifeCare patient?
New patients are welcome. However, you must have a documented history of Wegovy 2.4mg use and a clinical assessment confirming suitability for the 7.2mg dose.
Q: What if I am not currently on Wegovy 2.4mg?
Wegovy 7.2mg is specifically for patients who have plateaued on the 2.4mg dose. If you are not currently on Wegovy 2.4mg, our medical team can discuss whether medical weight management — starting with an appropriate first-line approach — is suitable for you.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Wegovy (semaglutide) is a prescription-only medicine. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Individual results vary. NuLifeCare is an MOH-registered medical clinic in Singapore. The Named Patient Programme is administered by HSA and subject to regulatory approval.
Interested in Wegovy 7.2mg? Contact NuLifeCare Today
If you have been on Wegovy 2.4mg and your weight loss has stalled, Wegovy 7.2mg could be the next step in your weight management journey. NuLifeCare is accepting expressions of interest now. The entire import process — including HSA approval, product shipment, and delivery to our clinic — may take up to eight weeks, so early registration is recommended.
Contact NuLifeCare
Website: www.nulifecare.com.sg
Visit our Contact Us page to book your consultation or enquire about Wegovy 7.2mg.